Hims & Hers shares are higher today as markets continue to reprice the company around a fresh catalyst: loosening peptide-related restrictions and a formal FDA review path for peptide compounding. The latest leg of the move follows the FDA’s update that removed 12 peptides from Category 2, with the change effective April 22, 2026, and upcoming Pharmacy Compounding Advisory Committee (PCAC) review steps beginning in July 2026—an opening that investors see as supportive for telehealth platforms that can quickly scale new cash-pay offerings. (fda.gov)

Peptide therapies have become a high-attention area in consumer wellness and telehealth, and the market is betting that a clearer regulatory runway could allow Hims to expand into additional compounded peptide products, potentially creating a new category to offset slowing economics in compounded GLP-1 weight-loss offerings. The stock’s rally has been closely linked to this thesis, with analysts highlighting the long-term potential if peptide access broadens and the company can repurpose existing capabilities toward a new set of therapies. (finance.yahoo.com)

Key swing factors are (1) the exact scope and timing of PCAC reviews (starting July 2026) and any subsequent FDA decisions, (2) whether Hims can launch peptide offerings at attractive unit economics, and (3) how regulators and incumbents respond if compounded peptide demand scales. Separately, investors will also be sensitive to any compliance, security, or reputational developments after the company disclosed a customer-support-system incident earlier in April 2026. (getpeptideclarity.com)